{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:31:55Z","timestamp":1787311915825,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03852-w","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T09:02:34Z","timestamp":1728464554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Hye In","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mijin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nak Gyeong","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihyeon","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-La","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ji","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"3852_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrclinonc.2015.223","volume":"13","author":"EF Smit","year":"2016","unstructured":"Smit EF, Baas P (2016) Lung cancer in 2015: bypassing checkpoints, overcoming resistance, and honing in on new targets. Nat Rev Clin Oncol 13:75\u201376. https:\/\/doi.org\/10.1038\/nrclinonc.2015.223","journal-title":"Nat Rev Clin Oncol"},{"key":"3852_CR2","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jtho.2020.03.006","volume":"15","author":"J Remon","year":"2020","unstructured":"Remon J, Passiglia F, Ahn MJ et al (2020) Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC Expert Panel and recommendations. J Thorac Oncol 15:914\u2013947. https:\/\/doi.org\/10.1016\/j.jtho.2020.03.006","journal-title":"J Thorac Oncol"},{"key":"3852_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/14737140.2016.1248945","volume":"16","author":"B Keam","year":"2016","unstructured":"Keam B, Jung H, Nam BH (2016) Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. Expert Rev Anticancer Ther 16:1217\u20131218. https:\/\/doi.org\/10.1080\/14737140.2016.1248945","journal-title":"Expert Rev Anticancer Ther"},{"key":"3852_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17:389\u2013399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"3852_CR5","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/nejmoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018\u20132028. https:\/\/doi.org\/10.1056\/nejmoa1501824","journal-title":"N Engl J Med"},{"key":"3852_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/labinvest.2013.130","volume":"94","author":"V Velcheti","year":"2014","unstructured":"Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL (2014) Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 94:107\u2013116. https:\/\/doi.org\/10.1038\/labinvest.2013.130","journal-title":"Lab Invest"},{"key":"3852_CR7","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ejca.2014.01.018","volume":"50","author":"CY Yang","year":"2014","unstructured":"Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50:1361\u20131369. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.018","journal-title":"Eur J Cancer"},{"key":"3852_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Aisner DL et al (2023) NCCN Guidelines\u00ae insights: non-small cell lung cancer, Version 2.2023. J Natl Compr Canc Netw 21:340\u2013350. https:\/\/doi.org\/10.6004\/jnccn.2023.0020","journal-title":"J Natl Compr Canc Netw"},{"key":"3852_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1375642","volume":"7","author":"HI Kim","year":"2017","unstructured":"Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, Kim SW, Lee DH, Park K, Ahn MJ, Chung JH, Shong YK, Kim WG, Kim TH (2017) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology 7:e1375642. https:\/\/doi.org\/10.1080\/2162402x.2017.1375642","journal-title":"Oncoimmunology"},{"key":"3852_CR10","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00262-020-02802-6","volume":"70","author":"P Thuillier","year":"2021","unstructured":"Thuillier P, Joly C, Alavi Z, Crouzeix G, Descourt R, Quere G, Kerlan V, Roudaut N (2021) Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol Immunother 70:2023\u20132033. https:\/\/doi.org\/10.1007\/s00262-020-02802-6","journal-title":"Cancer Immunol Immunother"},{"key":"3852_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","volume":"20","author":"M Grangeon","year":"2019","unstructured":"Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F (2019) Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clin Lung Cancer 20:201\u2013207. https:\/\/doi.org\/10.1016\/j.cllc.2018.10.002","journal-title":"Clin Lung Cancer"},{"key":"3852_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925","journal-title":"JAMA Oncol"},{"key":"3852_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28:583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"key":"3852_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12020-019-01871-7","volume":"64","author":"I Peir\u00f3","year":"2019","unstructured":"Peir\u00f3 I, Palmero R, Iglesias P, D\u00edez JJ, Sim\u00f3-Servat A, Mar\u00edn JA, Jim\u00e9nez L, Domingo-Domenech E, Mancho-Fora N, Nadal E, Villabona C (2019) Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 64:605\u2013613. https:\/\/doi.org\/10.1007\/s12020-019-01871-7","journal-title":"Endocrine"},{"key":"3852_CR15","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.ccr-21-0921","volume":"27","author":"J Luo","year":"2021","unstructured":"Luo J, Martucci VL, Quandt Z et al (2021) Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer. Clin Cancer Res 27:5131\u20135140. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-0921","journal-title":"Clin Cancer Res"},{"key":"3852_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107296","volume":"91","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Xia R, Xiao H, Pu D, Long Y, Ding Z, Liu J, Ma X (2021) Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. Int Immunopharmacol 91:107296. https:\/\/doi.org\/10.1016\/j.intimp.2020.107296","journal-title":"Int Immunopharmacol"},{"key":"3852_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.21037\/jtd-23-254","volume":"15","author":"Z Li","year":"2023","unstructured":"Li Z, Xia Y, Xia M, Liu C, Wang T, Liu Y, Ren Y (2023) Immune-related thyroid dysfunction is associated with improved long-term prognosis in patients with non-small cell lung cancer treated with immunotherapy: a systematic review and meta-analysis. J Thorac Dis 15:690\u2013700. https:\/\/doi.org\/10.21037\/jtd-23-254","journal-title":"J Thorac Dis"},{"key":"3852_CR18","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","volume":"12","author":"S Teraoka","year":"2017","unstructured":"Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K (2017) Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol 12:1798\u20131805. https:\/\/doi.org\/10.1016\/j.jtho.2017.08.022","journal-title":"J Thorac Oncol"},{"key":"3852_CR19","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.ccr-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412\u20137420. https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-1624","journal-title":"Clin Cancer Res"},{"key":"3852_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3852_CR21","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM, ATAT American Thyroid Association Task Force on Thyroid Hormone Replacement (2014) Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid 24:1670\u20131751. https:\/\/doi.org\/10.1089\/thy.2014.0028","journal-title":"Thyroid"},{"key":"3852_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"3852_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jtho.2016.04.007","volume":"11","author":"JM Sun","year":"2016","unstructured":"Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, Dolled-Filhart M, Emancipator K, Wu D, Weiner R, Frisman D, Kim HK, Choi YS, Shim YM, Kim J (2016) Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol 11:1003\u20131011. https:\/\/doi.org\/10.1016\/j.jtho.2016.04.007","journal-title":"J Thorac Oncol"},{"key":"3852_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/his.15146","volume":"84","author":"S Hwang","year":"2024","unstructured":"Hwang S, Hong TH, Kim HK, Cho J, Lee G, Choi S, Park S, Lee SH, Lee Y, Jeon YJ, Lee J, Park SY, Cho JH, Choi YS, Kim J, Zo JI, Shim YM, Choi YL (2024) PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system. Histopathology 84:1013\u20131023. https:\/\/doi.org\/10.1111\/his.15146","journal-title":"Histopathology"},{"key":"3852_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin 67:93\u201399. https:\/\/doi.org\/10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"3852_CR26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/(SICI)1097-0258(19961015)15:19<1999::AID-SIM353>3.0.CO;2-D","volume":"15","author":"M Schemper","year":"1996","unstructured":"Schemper M, Stare J (1996) Explained variation in survival analysis. Stat Med 15:1999\u20132012. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19961015)15:19<1999::AID-SIM353>3.0.CO;2-D","journal-title":"Stat Med"},{"key":"3852_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361\u2013387. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","journal-title":"Stat Med"},{"key":"3852_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630136","volume":"11","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Yamada T, Takumi C, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K (2021) Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy: a retrospective study. Front Oncol 11:630136. https:\/\/doi.org\/10.3389\/fonc.2021.630136","journal-title":"Front Oncol"},{"key":"3852_CR29","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2021.39.15_suppl.2545","volume":"39","author":"W Alexander","year":"2021","unstructured":"Alexander W, Attwood K, Catalfamo K, Dy GK, George S, Ernstoff MS, Abdou Y (2021) Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors. J Clin Oncol 39:2545. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2545","journal-title":"J Clin Oncol"},{"key":"3852_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.013","volume":"103","author":"D \u00c1lvarez-Sierra","year":"2019","unstructured":"\u00c1lvarez-Sierra D, Mar\u00edn-S\u00e1nchez A, Ruiz-Bl\u00e1zquez P, de Jes\u00fas GC, Iglesias-Felip C, Gonz\u00e1lez \u00d3, Casteras A, Costa RF, Nuciforo P, Colobran R, Pujol-Borrell R (2019) Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun 103:102285. https:\/\/doi.org\/10.1016\/j.jaut.2019.05.013","journal-title":"J Autoimmun"},{"key":"3852_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","author":"Y Yasuda","year":"2021","unstructured":"Yasuda Y, Iwama S, Sugiyama D et al (2021) CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb7495","journal-title":"Sci Transl Med"},{"key":"3852_CR32","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","volume":"48","author":"P Campredon","year":"2019","unstructured":"Campredon P, Mouly C, Lusque A, Bigay-Game L, Bousquet E, Mazi\u00e8res J, Caron P (2019) Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients. Press Med 48:e199\u2013e207. https:\/\/doi.org\/10.1016\/j.lpm.2018.10.019","journal-title":"Press Med"},{"key":"3852_CR33","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.3892\/ol.2019.10466","volume":"18","author":"T Sakakida","year":"2019","unstructured":"Sakakida T, Ishikawa T, Uchino J, Chihara Y, Komori S, Asai J, Narukawa T, Arai A, Kobayashi T, Tsunezuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K (2019) Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. Oncol Lett 18:2140\u20132147. https:\/\/doi.org\/10.3892\/ol.2019.10466","journal-title":"Oncol Lett"},{"key":"3852_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4:173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"3852_CR35","doi-asserted-by":"publisher","first-page":"e1620","DOI":"10.1210\/clinem\/dgab829","volume":"107","author":"S Iwama","year":"2022","unstructured":"Iwama S, Kobayashi T, Yasuda Y et al (2022) Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J Clin Endocrinol Metab 107:e1620\u2013e1630. https:\/\/doi.org\/10.1210\/clinem\/dgab829","journal-title":"J Clin Endocrinol Metab"},{"key":"3852_CR36","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/jco.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"3852_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/jco.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K et al (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36:633\u2013641. https:\/\/doi.org\/10.1200\/jco.2017.75.3384","journal-title":"J Clin Oncol"},{"key":"3852_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","volume":"122","author":"N Okada","year":"2020","unstructured":"Okada N, Iwama S, Okuji T et al (2020) Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer 122:771\u2013777. https:\/\/doi.org\/10.1038\/s41416-020-0736-7","journal-title":"Br J Cancer"},{"key":"3852_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216954","volume":"14","author":"I Yamauchi","year":"2019","unstructured":"Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N (2019) Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE 14:e0216954. https:\/\/doi.org\/10.1371\/journal.pone.0216954","journal-title":"PLoS ONE"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03852-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T07:05:15Z","timestamp":1731740715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03852-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3852"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03852-w","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Boards of SMC (2016-12-112) and AMC (2016-1254).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"260"}}